23:15 , Jul 15, 2019 |  BC Extra  |  Company News

Management tracks: GSK, Orphazyme, Kymera and more

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined to confirm news reports stating it will appoint Jonathan Symonds as chairman to succeed Philip Hampton, who has served in the role since 2015. The Financial Times and Bloomberg, citing...
22:34 , Mar 7, 2019 |  BC Extra  |  Preclinical News

Beyond cancer: CAR T cells treat lupus in mice

University of Tennessee researchers have shown that CD19-targeted CAR T cells could help treat lupus, suggesting the approach could be applied to diseases beyond cancer. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by...
19:35 , Jan 24, 2019 |  BC Innovations  |  Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks. Cabaletta spun...
23:44 , Jan 23, 2019 |  BC Extra  |  Company News

Management tracks: Cabaletta, Sage, MyoKardia

Autoimmune cell therapy company Cabaletta Bio Inc. (Radnor, Pa.) hired Anup Marda as CFO. He was VP and head of global corporate financial planning and analysis at Bristol-Myers Squibb Co. (NYSE:BMY). Marda succeeds interim CFO...
19:06 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Jan....
22:05 , Jan 3, 2019 |  BC Extra  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Thursday....
22:24 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Ambys, Foghorn

Liver regenerative medicine company Ambys Medicines (Redwood City, Calif.) hired Jeff Jonker as president, CEO and a director. He succeeds Interim CEO Jeffrey Tong, who will become chairman. Jonker was president of NGM Biopharmaceuticals Inc....
22:03 , Nov 15, 2018 |  BC Extra  |  Company News

Management tracks: Spark, Cabaletta

Spark Therapeutics Inc. (NASDAQ:ONCE) said in an SEC filing that COO John Furey will resign, effective Jan. 1. He will remain a consultant for the gene therapy company through June 28. Cabaletta Bio Inc. (Radnor,...
18:30 , Nov 9, 2018 |  BC Week In Review  |  Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies for B cell-mediated autoimmune diseases. Cabaletta's co-founders include Michael Milone, an...
20:09 , Nov 8, 2018 |  BC Extra  |  Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies for B cell-mediated autoimmune diseases. Cabaletta's co-founders include Michael Milone, an...